Instituto Portugues de Oncologia do Porto ( Site 2202)

Porto 4200-072

1 studies enrolling now · 1 studies all time

What they study most

Triple-Negative Breast Cancer

Studies at this site

• Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) — Recruiting now